Dutch/Belgian biotech company Pluriomics has raised an additional 2.5 million euro in funding from Belgian VCs SFPI-FPIM and SambrInvest to speed up growth.
Pluriomics is a spin-off from the Leiden University Medical Center (LUMC). It uses stem cell technology, disease modeling and cell-based assays development for cardiovascular drug discovery.
Heart cells
For instance, it does tests with artificial cells, similar to human heart cells. “Tests on these cells have the potential to accelerate therapeutic drug discovery, lower the expenses of development, and in addition, reduce the need for laboratory animals”, explained co-founder and now CEO Stefan Braam back in 2014.
The company will strengthen its R&D and commercial team in Leiden while setting-up a production facility in Gosselies (Belgium).
In 2014 Pluriomics already raised a series A round of 4 million euro. Last year it received a massive 3.2 million euro grant from the EU.